Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 2360270 | [The incidence of fibromyalgia in patients admitted to a rheumatology department]. | 1990 May 21 | One hundred patients admitted consecutively to Kong Christian X Hospital for rheumatic conditions were examined for symptoms of fibromyalgia. 47% of the patients had not only histories of pain in three or more anatomically separate regions but also presence of at least seven tender points in the soft tissues on palpation of 15 sites of predilection for tender points. This investigation suggests a high incidence of secondary fibromyalgia in patients admitted on account of various rheumatic conditions. | |
| 2692130 | Rheumatoid arthritis and Proteus: a possible aetiological association. | 1989 | The presence of specific anti-Proteus antibodies in active, rheumatoid arthritis (RA) patients, has been demonstrated by four different techniques: indirect bacterial agglutination, ELISA, Western blotting and immunofluorescence. Furthermore, anti-HLA-DR4 tissue typing sera have been shown to bind to Proteus microorganisms, thereby suggesting some molecular similarity or cross-reactivity between bacteria and HLA antigens. The concept is proposed that Proteus-reactive arthritis occurs during active phases of RA and tissue damage is mediated through immunological activity involving HLA antigens. | |
| 3023512 | 1,25-Dihydroxyvitamin D3 receptors in lymphocytes from patients with rheumatoid arthritis. | 1986 Dec | It has been previously found that activation of human lymphocytes in vitro causes the expression of receptors for the hormone 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], and that 1,25(OH)2D3 has immunoregulatory properties including the ability to inhibit interleukin-2, to suppress lymphocyte proliferation, and to inhibit antibody production. In the present study we found that 13 of a group of 17 (76%) seropositive patients with rheumatoid arthritis had lymphocytes that possessed 1,25(OH)2D3 receptors (without activation in vitro) compared with only three of 17 (18%) normal individuals. The biochemical characteristics of the 1,25(OH)2D3 receptor, including affinity, sedimentation coefficient, and DNA-binding properties in the rheumatoid arthritis lymphocytes were indistinguishable from those established for this receptor in the classic target tissue of the hormone. This finding raises the possibility that 1,25(OH)2D3, acting through its receptor, might play a previously unsuspected role on lymphocytes of patients with rheumatoid arthritis. | |
| 2016605 | Total hip arthroplasty. A comparison between cemented and press-fit noncemented fixation. | 1991 Mar | This study compares cemented (Charnley) with noncemented (Honart Patel-Garches) total hip arthroplasty. 150 patients with osteoarthritis, rheumatoid arthritis, and miscellaneous conditions were randomized into either group with 75 in each. Patients were evaluated over 5 postoperative years with examinations at 6 months, at 1 year, and then annually. Each examination involved clinical assessment, objective gait analysis, and radiographic examination. The Charnley group improved faster than the HP-Garches group during the first 2 years. At the last evaluation the results were excellent or good in 79% in the Charnley group and 70% in the HP-Garches group. In the HP-Garches group midthigh pain occurred in 64%. Five patients with Charnley prostheses (6.7%) and 14 patients with HP-Garches prostheses (18.7% had revision surgery to correct mechanical loosening. Standard radiography revealed radiolucent zones in both groups, but this could not be related to the clinical outcome despite radiolucency being present in all noncemented replacements on the femoral side. Objective gait analysis confirmed inferior clinical results at 6 months in the HP-Garches group. There was no significant difference between the groups at the most recent evaluation. Our findings are not consistent with earlier optimistic expectations on press-fit noncemented total hip arthroplasties. | |
| 2591113 | Subcutaneous fat biopsy in the diagnosis of amyloidosis secondary to chronic arthritis. | 1989 Jul | Subcutaneous fat biopsy was investigated for its sensitivity in giving a diagnosis in 44 consecutive patients with rheumatoid arthritis or ankylosing spondylitis suspected of systemic amyloidosis. In 26 of these patients amyloidosis could be demonstrated by fat or rectal biopsy or biopsies from organs suspected of amyloid deposition. Fourteen of the 26 (54%) fat biopsy specimens of the patients with amyloidosis were positive after staining with Congo red and 22 (85%) of the rectal biopsy specimens were positive. All 12 kidney biopsy specimens and 4 biopsy specimens from other organs of these 26 patients were positive for amyloidosis. In 2 patients with a negative rectal biopsy specimen, fat biopsy would have obviated the need for a more invasive biopsy. All patients experienced fat biopsy as less demanding compared to other biopsy procedures. These results imply that in patients with chronic arthritis subcutaneous fat biopsy is a useful screening procedure. In this patient group fat biopsy is less sensitive for the diagnosis of amyloidosis compared to rectal biopsy. | |
| 3132277 | Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and | 1988 May 21 | Serum titres of IgA are raised in ankylosing spondylitis and increased titres of antibodies to klebsiella have also been reported. The humoral response was investigated in ankylosing spondylitis and other inflammatory disorders. IgA antibodies to klebsiella pneumoniae K43 were measured in patients with ankylosing spondylitis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis and in controls. Significantly raised median titres of anti-klebsiella IgA, measured as optical density at 405 nm with an enzyme linked immunosorbent assay (ELISA), were seen among the patients with ankylosing spondylitis (0.7), Crohn's disease (0.8), rheumatoid arthritis (0.6), and ulcerative colitis (0.8) compared with controls (0.4). Activity of disease in ankylosing spondylitis and titres of anti-klebsiella IgA were not correlated. In contrast, titres of anti-klebsiella IgM were significantly lower in patients with ankylosing spondylitis and ulcerative colitis. The increase in the titres of anti-klebsiella IgA may be due to increased permeability of the gut to bacterial antigens, leading to an increased IgA response in the gut mucosa and permitting the release of IgA into the circulation. As the increased antibody titres were seen in Crohn's disease and rheumatoid arthritis as well as in ankylosing spondylitis the response may be nonspecific, occurring because of possible underlying inflammatory bowel disease in these conditions. | |
| 2673662 | The effect of different indomethacin formulations in young and elderly patients: a compara | 1989 | In a double-blind, crossover trial a controlled-release multiple-units indomethacin formulation (50 mg twice daily) was compared with conventional capsules (25 mg twice daily with 50 mg in the evening) in 12 young and 18 elderly in-patients with rheumatoid arthritis. Earlier findings that younger patients preferred a slow-release formulation and the elderly a standard formulation could not be confirmed. As a whole, the duration of morning stiffness was reduced more (p = 0.02) with the controlled-release formulation than with the conventional formulation. During the treatment period (7 days), 4 patients reported side-effects from the conventional capsules, 3 from the controlled-release formulation, and 6 from both treatments; 53% of the patients preferred the controlled-release formulation, while 20% preferred the conventional capsule (p = 0.046). | |
| 3829471 | Response to apheresis: problems of assessment in immune disease. | 1986 | Systemic lupus erythematosus (SLE) was one of the first diseases to be treated by plasmapheresis, because of the abundance of serological disturbances, and the strong evidence that tissue damage is related to the deposition of immune complexes. Early results in small, uncontrolled studies were promising, but no large-scale controlled trials have yet been reported. The conditions for which well-controlled trials are now available are either diseases affecting a single organ-system, in which clinical abnormalities are readily measurable, such as Guillain-Barre syndrome, or conditions in which serological abnormalities correlate closely with clinical disturbances, such as myasthenia gravis. Definitive answers are also available in rheumatoid arthritis, where many years of clinical experience have led to the development of well-validated indices of clinical activity. Many studies of SLE suggest that serological abnormalities, though important, are often not quantitatively linked to the clinical manifestations of the disease. Attempts to develop indices of clinical activity for SLE are handicapped by the range of different organ systems which may be involved. Progress in the development of clinical trials of plasmapheresis in SLE is most likely to result from multicenter cooperative groups, which will have the capacity to study large enough numbers of patients for adequate stratification, and from the development and validation of indices of clinical activity, which will make possible the quantitation of clinical response, and the measurement of the rate of accumulation of permanent organ damage. | |
| 2912250 | Observations of interactions of depressed women with their children. | 1989 Jan | Dysfunctional interactions between mothers with major affective disorders and their children may contribute to the children's high risk of disorder. This study investigated the behavior of mothers with recurrent unipolar depression, bipolar disorder, or chronic medical illness and of normal subjects toward their children during a directly observed conflict discussion task. In addition, lifetime history of depression, current mood, and chronic stress were investigated as predictors of maternal interaction. Unipolar depressed women displayed relatively more negative, less positive, and less task-focused behaviour toward their children. Current mood and chronic stress, more than psychiatric history, contributed to the prediction of interaction style. | |
| 1875281 | The kinetics of flurbiprofen in synovial fluid. | 1991 Jun | Steady state plasma and synovial fluid flurbiprofen concentrations obtained from 26 rheumatoid arthritis patients receiving 100 mg of flurbiprofen b.i.d. were analyzed using the NONMEM program. Only one synovial fluid sample per patient was available. Population estimates for the plasma parameters, clearance, volume of distribution, and elimination half-life were 1.75 L hr-1, 11.9 L, and 4.8 hr, respectively, and the corresponding interindividual variances in these parameters were 29, 19 and 23%, respectively. The apparent elimination half-life from synovial fluid was 7.1 hr. After accounting for interindividual variability there was a residual variability of approximately 40% in both the plasma and synovial fluid concentrations. | |
| 1657615 | Biased T cell receptor V alpha region repertoire in the synovial fluid of rheumatoid arthr | 1991 Nov | Synovial T lymphocytes seem to contribute to the pathogenesis of rheumatoid arthritis (RA). Since very little is known about the structural heterogeneity of their T cell antigen receptors (TcR), we analyzed TcR alpha chain mRNA of synovial fluid T cells from two RA patients. TcR alpha chain cDNA was amplified by the polymerase chain reaction with single-sided specificity for the alpha chain constant (C alpha) gene segment, and the nucleotide sequences of 51 functionally rearranged cDNA clones were determined. Twenty different V alpha genes and 26 different J alpha gene segments were utilized in these cDNA clones. Three of the V alpha gene segments which are frequently (8%-17% total) expressed in synovial fluid T cells have rarely been found in the TcR repertoire of peripheral blood T cells from healthy individuals. The T cell responses in the rheumatic synovia analyzed here are not oligoclonal, but the usage of TcR V alpha genes is biased. | |
| 1685199 | [Recurrent hyperkalemia in the course of rheumatoid arthritis--a case report]. | 1991 Aug | A 69-year-old woman with advanced rheumatoid arthritis (RA) suffered two episodes of hyperkalemic hyperchloremic metabolic acidosis (HCMA). Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were markedly suppressed in the first episode occurring in paralell with the administration of metoprolol during piroxicam and lobenzarit (CCA) therapy. Rechallenge with diclofenac sodium and CCA lead to the second hyperkalemia, but no significant suppression of the renin-aldosterone axis was seen at that time. This suggests that the different mechanisms contribute to the development of these episodes, including the tubulo-interstitial injury which is not uncommon in RA. The combined use of nonsteroidal anti-inflammatory drugs (NSAIDs) and beta-adrenergic blockers may increase the risk of life-threatening hyperkalemia through their suppressive effect on the renin-aldosterone system, whereas the concomitant administration of CCA with NSAIDs through the impairment in the renal tubular function. These drugs should be most carefully given to patients with a latent defect in renal potassium excretion. | |
| 2224404 | The inhibition of NK cell function by azathioprine during the treatment of patients with r | 1990 Oct | Treatment with azathioprine of patients with rheumatoid arthritis leads to a dramatic reduction in the 4 h NK cytotoxicity against K562 cells. The 24 h cytotoxicity against K562 and U937 cells, however, remains intact. The generation of cell-free supernatant cytotoxic factor(s) after incubating non-adherent mononuclear cells with U937 cells for 24 h is similar in the azathioprine patients and the controls. A large part of this supernatant cytotoxicity is due to tumour necrosis factor alpha which can be inhibited by a specific monoclonal antibody. The mechanism of the reduced 4 h NK cytotoxicity remains unknown but is probably not related to the anti-inflammatory properties of azathioprine. | |
| 3491696 | Characterization of synovial T lymphocytes in rheumatoid arthritis. I. Production of IL-2 | 1986 Jun | Lymphocytes obtained from the peripheral blood (PBL) or synovial fluids (SFL) of patients with rheumatoid arthritis (RA) or other inflammatory joint diseases were compared with the PBL from normal individuals, by cloning under limiting dilution conditions in the presence of interleukin 2 (IL-2). The precursor frequency estimates of IL-2 responsive cells from these sources did not differ appreciably. However there were marked differences in the surface marker phenotypes of the clones derived from the PBL as compared to SFL. There was a predominance of OKT4-8+ cells in SFL from RA and non RA donors with inflammatory joint disease while PBL from all sources showed a marked prevalence of OKT4+8- cells. Comparison of precursor frequencies in the presence of PBL and SFL indicated that there were variations in the capacities of the SFL and PBL IL-2 dependent cells to grow on these fillers. SFL derived cells grew equally well on PBL or SFL filler, while PBL clones grew efficiently only on PBL fillers. Collectively these results indicate that there are marked differences in the surface phenotypes and growth requirements of IL-2 responsive SFL as compared to PBL. | |
| 3789819 | Superoxide dismutase isoenzymes of the synovial fluid in rheumatoid arthritis and in react | 1986 Oct | The activity of superoxide dismutase isoenzymes was determined in knee joint synovial fluid from 21 patients with rheumatoid arthritis, nine patients with reactive arthritides, and from 17 patients before arthroscopy or arthrotomy for suspected meniscal or ligament injury (controls). Extracellular superoxide dismutase was the major isoenzyme and accounted for about 80% of the total superoxide dismutase activity in the controls. The pattern of the superoxide dismutase isoenzymes was significantly different in rheumatoid arthritis, extracellular (EC) superoxide dismutase being half, CuZn superoxide dismutase double, and the total superoxide dismutase activity a third lower than the activity in the synovial fluid of the controls. The superoxide dismutase activities were similar in synovial fluid from the controls and from the patients with reactive arthritides. The total superoxide dismutase activity was almost three times higher in control synovial fluid than in normal human plasma, but 300 times lower than in human tissues. | |
| 2057665 | [Corticosteroid therapy of various systemic diseases (non-neoplastic, noninfectious)]. | 1991 May | The authors evoke how the corticosteroids work (as antiinflammatory and immunosuppressive agents) and how to prescribe them, orally, intravenously, in association with an antimitotic drug. They insist on the suspended and non curative effects of corticotherapy, its side effects and the additive effect of the antimitotic drugs. They suggest different therapeutic programs against rheumatoid arthritis, Still's disease, lupus, dermatomyositis, Behçet's disease, Horton's disease and polymyalgia rheumatica. | |
| 2907220 | [The status of Churg-Strauss syndrome among other hypereosinophilic, granulomatous and vas | 1988 Nov | The Churg-Strauss syndrome is a disorder characterized by hypereosinophilia and systemic vasculitis occurring in patients with asthma and allergic rhinitis. Only few patients are identified as having this syndrome. The three histological criteria are necrotizing vasculitis, tissue infiltration by eosinophils, and extravascular granulomas; they often do not coexist in one patient. To find a clinical approach to diagnosis, it is necessary to exclude other disorders with hypereosinophilia, granulomas, and vasculitis. In regard to this clinical viewpoint it seems that the syndrome is not as rare as may be assumed according to the relevant autopsy findings. Two cases are reported in which the Churg-Strauss syndrome developed together with rheumatoid arthritis; in one case it was likely triggered by treatment with D-penicillamin. | |
| 2474393 | Assay of serum hyaluronic acid in clinical application. | 1989 May 31 | A sandwich-binding protein assay to determine the concentration of hyaluronic acid (HA) in body fluids has been developed. In this method, a hyaluronic acid binding protein (HABP) was adsorbed to the surface of a solid phase, and HA bound to HABP on the solid phase was detected by biotin-conjugated HABP. The method could assay HA levels within 6 hours using precoated microwells with HABP. HA could be determined in the range of 2-500 micrograms/l by this method using 50 microliters of serum. Within-run precision (CV) was 5.2-10.2%. The specificity of HABP to HA was confirmed by the elimination of the reaction with treatment by hyaluronidase digestion. Serum HA levels (median; range) of patients with rheumatoid arthritis (34; 2-187 micrograms/l) were shown to be higher than those with osteoarthritis (1; 1-21 micrograms/ml) and healthy controls (2; 1-8 micrograms/ml). No correlation between levels of HA and rheumatoid factor was found. HA was demonstrated to be a potential diagnostic marker for rheumatoid arthritis, and this HABP assay could be useful for determination of HA in clinical laboratory tests. | |
| 2075399 | [Immunomodulator effects of 2 kinds of interferon alpha on the in vitro synthesis of syste | 1990 Oct | The authors have studied the synthesis of interleukin 1 by articular and circulating macrophages and the effect of two types of interferon alpha (IF) on this synthesis in 20 patients with untreated rheumatoid arthritis (RA). The articular and especially systemic interleukin levels in the RA patients are significantly higher than those of the test subjects. Interferon modifies in a very different way the production of interleukin 1 in the patients and in the test subjects. This is linked with the in vitro experimental conditions as well as the increase in the IL1 levels in the patients. The authors discuss the perspective therapeutics offered by this modulation of interleukin production by interferon. | |
| 3359941 | Efficacy and tolerance of tiaprofenic acid during long term administration to rheumatoid a | 1988 | In a multicentre trial, tiaprofenic acid was administered in a dosage of 600 mg/day for 12 months to 109 patients with rheumatoid arthritis. The results in 79 patients, who did not receive any other non-steroidal anti-inflammatory drugs concomitantly, were assessed. Of the 79 patients, 11 withdrew from the study within one year. The reasons for withdrawal were personal reasons in 4 cases, side effects or abnormal laboratory values in 2, no change or aggravation of symptoms in 2, improvement of symptoms in 2, and identification of systemic lupus erythematosus in one. Overall improvement was definite in 27 patients (34.2%) and slight in 21 patients (26.6%). Overall usefulness was definite in 30 patients (38%) and slight in 27 patients (34.2%). The duration of morning stiffness, joint index and Lansbury activity index showed significant improvement after 6 months' administration. Side effects were observed in 2 cases (2.5%) and abnormal laboratory results were seen in 3 (3.8%). These disappeared on either continuation or discontinuation of treatment. |